B Cell Culture Method for Monoclonal Antibody Production

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing monoclonal antibodies targeting specific antigens, such as cancer cells, are time-consuming and inefficient, requiring immunization of animals, hybridoma formation, and recombination techniques, which can lead to immunological tolerance and individual toxicity issues, and do not effectively select B cells with high antigen affinity.

Innovation Solution

A method involving culturing B cells with specific antigens in the absence of IL-21 and IL-4, while using cytokines like IL-2, CD40, and BAFF receptor stimulation, followed by Fas stimulation, to efficiently produce B cell populations recognizing specific antigens, which can then be used to generate monoclonal antibodies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional methods using animal immunization and hybridoma formation are used, then monoclonal antibodies can be produced, but the process takes much time and requires complex procedures

Engineering Contradiction:
Improveproduction speed of monoclonal antibodiesVSAvoidtime required for immunization and hybridoma selection
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The invention extracts and utilizes human B cells that naturally produce high-affinity antibodies from human blood samples, eliminating the need for time-consuming animal immunization and hybridoma formation processes. This direct extraction approach allows rapid production of monoclonal antibodies within weeks rather than months or years.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The method performs preliminary enrichment of antigen-specific B cells from human blood before culture expansion. By pre-selecting B cells that naturally recognize the target antigen and culturing them under specific conditions (with IL-2, IL-7, and antigen stimulation), the invention prepares a concentrated population of antibody-producing cells in advance, accelerating subsequent monoclonal antibody production.

Inventive Principle:
Principle #10Preliminary action

2Reliability

If animal models are used for antibody production, then antibodies can be obtained, but individual toxicity and immunological tolerance issues arise

Engineering Contradiction:
Improvesafety and efficacy of antibody for human treatmentVSAvoidindividual toxicity and immunological rejection
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention copies the human immune system's natural antibody production mechanism by culturing human B cells in vitro. This approach generates human antibodies that are identical to those produced in the human body, ensuring they will not trigger immunological rejection or toxicity when administered to patients, unlike animal-derived antibodies.

Inventive Principle:
Principle #26Copying

Solution Approach 2:

The method utilizes the inherent capability of human B cells to self-produce high-affinity antibodies when stimulated with the target antigen and appropriate cytokines. By providing the right culture conditions (IL-2, IL-7, antigen), the B cells automatically differentiate and secrete monoclonal antibodies without requiring animal models or complex genetic manipulation.

Inventive Principle:
Principle #25Self-service

3Measurement precision

If conventional B cell culture methods with IL-21 and IL-4 are used, then B cells can be maintained, but the selectivity for high-affinity antigen-specific B cells is insufficient

Engineering Contradiction:
Improveselectivity for high-affinity antigen-specific B cellsVSAvoidcomplexity of culture conditions and selection process
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The invention changes the culture parameter profile by using IL-2 and IL-7 instead of the conventional IL-21 and IL-4 combination. This parameter change creates a selective environment that preferentially supports the survival and proliferation of high-affinity antigen-specific B cells while suppressing other B cell populations, achieving high selectivity through cytokine optimization rather than complex selection procedures.

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP3569700B1Method for producing b cell population and method for producing monoclonal antibody using the same
Publication Date: 2023.09.13 KANEKA CORP
  • EP3569700B1 patent drawingFigure 1~2
  • EP3569700B1 patent drawingFigure 3

AI summary

It is an object of the present invention to provide a method for efficiently producing a B cell population comprising B cells that recognize a specific antigen. According to the present invention, provided is a method for producing a B cell population, comprising: a step (c) of culturing a cell population comprising B cells together with a specific antigen in the absence of IL-21, in the absence of IL-4, and in the presence of a cytokine other than IL-21 and IL-4, while giving stimulation mediated by CD40 and a BAFF receptor to the cells; and a step (d) of culturing the cell population comprising B cells, while giving stimulation mediated by Fas to the cells, so as to obtain a B cell population comprising B cells that recognize the specific antigen.